BTIG lowered the firm’s price target on Alector (ALEC) to $5 from $16 and keeps a Buy rating on the shares. The TREM2 activation had little effect in Alzheimer’s disease, not a positive for the world of genome-wide association studies-driven medicine, the analyst tells investors in a research note, adding that the mechanism of ARIA-E may also need to be revisited.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: